| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology,*
Johns Hopkins
Hospital, Baltimore, Maryland; the Department of
Pathology,
University of Maryland, Baltimore,
Maryland; Department of Laboratory Medicine and
Pathology,
Mayo Clinic, Rochester, Minnesota;
and the Department of Medicine,§
University of
California San Diego, La Jolla, California
Astrocytic tumors occasionally arise in the central nervous system following radiotherapy. It is not clear if these gliomas represent a unique molecular genetic subset. We identified nine cases in which an astrocytoma arose within ports of previous radiation therapy, with total doses ranging from 2400 to 5500 cGy. Irradiated primary lesions included craniopharyngioma, pituitary adenoma, Hodgkin's lymphoma, ependymoma, pineal neoplasm, rhabdomyosarcoma, and three cases of lymphoblastic malignancies. Patients ranged from 9 to 60 years of age and developed secondary tumors 5 to 23 years after radiotherapy. The 9 postradiation neoplasms presented as either anaplastic astrocytoma (3 cases) or glioblastoma multiforme (6 cases). Two of the latter contained malignant mesenchymal components. We performed DNA sequence analysis, differential polymerase chain reaction (PCR), and quantitative PCR on DNA from formalin-fixed, paraffin-embedded tumors to evaluate possible alterations of p53, PTEN, K-ras, EGFR, MTAP, and p16 (MTS1/CDKN2) genes. By quantitative PCR, we found EGFR gene amplification in 2 of 8 tumors. One of these demonstrated strong immunoreactivity for EGFR. Quantitative PCR showed chromosome 9p deletions including p16 tumor suppressor gene (2 of 7 tumors) and MTAP gene (3 of 7). Five of 9 tumors demonstrated diffuse nuclear immunoreactivity for p53 protein. Sequencing of the p53 gene in these 9 cases revealed a mutation in only one of these cases, a G-to-A substitution in codon 285 (exon 8). Somewhat unexpectedly, no mutations were identified in PTEN, a commonly altered tumor suppressor gene in de novo glioblastoma multiformes. Unlike some radiation-induced tumors, no activating point mutations of the K-ras proto-oncogene or base pair deletions of tumor suppressor genes were noted. These radiation-induced tumors are distinctive in their high histological grade at clinical presentation. The spectrum of molecular genetic alterations appears to be similar to that described in spontaneous high grade astrocytomas, especially those of the de novo type.
This article has been cited by other articles:
 |
|
 |
|
  N. Gonin-Laurent, A. Gibaud, M. Huygue, S. H. Lefevre, M. Le Bras, L. Chauveinc, X. Sastre-Garau, F. Doz, L. Lumbroso, S. Chevillard, et al. Specific TP53 mutation pattern in radiation-induced sarcomas Carcinogenesis, June 1, 2006; 27(6): 1266 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Worsham, K. M. Chen, N. Tiwari, G. Pals, J. P. Schouten, S. Sethi, and M. S. Benninger Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 409 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Subhi, B. Tang, B. R. Balsara, D. A. Altomare, J. R. Testa, H. S. Cooper, J. P. Hoffman, N. J. Meropol, and W. D. Kruger Loss of Methylthioadenosine Phosphorylase and Elevated Ornithine Decarboxylase Is Common in Pancreatic Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7290 - 7296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Gutmann, C. D. James, M. Poyhonen, D. N. Louis, R. Ferner, A. Guha, S. Hariharan, D. Viskochil, and A. Perry Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1 Neurology, November 25, 2003; 61(10): 1397 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Illei, V. W. Rusch, M. F. Zakowski, and M. Ladanyi Homozygous Deletion of CDKN2A and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas Clin. Cancer Res., June 1, 2003; 9(6): 2108 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Christopher, P. Diegelman, C. W. Porter, and W. D. Kruger Methylthioadenosine Phosphorylase, a Gene Frequently Codeleted with p16cdkN2a/ARF, Acts as a Tumor Suppressor in a Breast Cancer Cell Line Cancer Res., November 15, 2002; 62(22): 6639 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Maher, F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. Cavenee, and R. A. DePinho Malignant glioma: genetics and biology of a grave matter Genes & Dev., June 1, 2001; 15(11): 1311 - 1333. [Full Text] [PDF]
|
|
|
|
|
|
P. Chen, K. Aldape, J. K. Wiencke, K. T. Kelsey, R. Miike, R. L. Davis, J. Liu, A. Kesler-Diaz, M. Takahashi, and M. Wrensch Ethnicity Delineates Different Genetic Pathways in Malignant Glioma Cancer Res., May 1, 2001; 61(10): 3949 - 3954. [Abstract] [Full Text]
|
|
|
|
|
|
C. Raffel, L. Frederick, J. R. O'Fallon, P. Atherton-Skaff, A. Perry, R. B. Jenkins, and C. D. James Analysis of Oncogene and Tumor Suppressor Gene Alterations in Pediatric Malignant Astrocytomas Reveals Reduced Survival for Patients with PTEN Mutations Clin. Cancer Res., December 1, 1999; 5(12): 4085 - 4090. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
